Union européenne - français - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - un maximum de trois des éléments suivants purifié inactivé de la fièvre aphteuse, la maladie de souches de virus: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o taiwan 3/97 ≥ 6 pd50*; a22 irak ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; une dinde 14/98 ≥ 6 pd50*; asie 1 shamir ≥ 6 pd50*; sat2, lorsqu'il l'arabie saoudite ≥ 6 pd50*; * pd50 – protectrice de 50% de la dose chez les bovins, comme décrit dans la ph. eur. monographie de 0063. - immunologiques - pigs; cattle; sheep - immunisation active des bovins, ovins et porcins à partir de l'âge de 2 semaines contre la fièvre aphteuse pour réduire les signes cliniques.

Union européenne - français - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals pour felidae, - chats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Union européenne - français - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals pour felidae, - chats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

beijing institue biological products co.,ltd. - inactivated sars-cov-2 antigen - suspension injectable - 0.5ml/dose - antiinfectieux generaux a usage systemique - vaccins - covid-19 vaccine (vero cell) inactivated est indiqué pour l'immunisation active pour la prévention de la covid-19 causée par le virus sars-cov-2, chez les personnes âgées de 18 ans et plus. l'utilisation de ce vaccin doit être conforme aux recommandations officielles.

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

beijing institue biological products co.,ltd. - inactivated sars-cov-2 antigen - suspension injectable - 0.5ml/dose - antiinfectieux generaux a usage systemique - vaccins - covid-19 vaccine (vero cell) inactivated est indiqué pour l'immunisation active pour la prévention de la covid-19 causée par le virus sars-cov-2, chez les personnes âgées de 18 ans et plus. l'utilisation de ce vaccin doit être conforme aux recommandations officielles.

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

beijing institue biological products co.,ltd. - inactivated sars-cov-2 antigen - suspension injectable - 0.5ml/dose - antiinfectieux generaux a usage systemique - vaccins - covid-19 vaccine (vero cell) inactivated est indiqué pour l'immunisation active pour la prévention de la covid-19 causée par le virus sars-cov-2, chez les personnes âgées de 18 ans et plus. l'utilisation de ce vaccin doit être conforme aux recommandations officielles.

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

beijing institue biological products co.,ltd. - inactivated sars-cov-2 antigen - suspension injectable - 0.5ml/dose - antiinfectieux generaux a usage systemique - vaccins - covid-19 vaccine (vero cell) inactivated est indiqué pour l'immunisation active pour la prévention de la covid-19 causée par le virus sars-cov-2, chez les personnes âgées de 18 ans et plus. l'utilisation de ce vaccin doit être conforme aux recommandations officielles.

Union européenne - français - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccins - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Union européenne - français - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - les cochons - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Union européenne - français - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antigènes de surface du virus de la grippe (hémagglutinine et neuraminidase) de la souche a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccins - immunisation active contre le sous-type h5n1 du virus grippal a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.